|
Malignant neoplasm of stomach
|
0.320 |
AlteredExpression
|
disease |
BEFREE |
MIA and GW112 were overexpressed in 10 (25%) and 22 (55%) of 40 GC samples, and the overexpression of these two genes was associated with tumor stage, respectively.
|
16210872 |
2005 |
|
Malignant neoplasm of stomach
|
0.320 |
AlteredExpression
|
disease |
BEFREE |
Levels of MIA were raised in a small proportion of serum samples from patients with GC (4/69, 5.8%).
|
16331256 |
2006 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
As expression of MIA and MMP-10 is narrowly restricted in cancer, these two molecules may be good therapeutic targets for GC.
|
16331256 |
2006 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In addition, the probability of malignancy of benign lesions, preinvasive lesions (AAH, AIS) and invasive lesions (MIA, IA) was totally different (49.40±38.41% vs 80.22±13.55% vs 88.17±17.31%).
|
31529684 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Although MIA gene family members have several tumor-related functions, their detailed roles in malignancies remain poorly elucidated.
|
27145272 |
2016 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Additionally, <i>in vitro</i> anticancer activity of the complexes were evaluated by SRB assay on selected cancer cell lines viz., HeLa (cervical), MIA-PA-CA-2 (pancreatic), MCF-7 (breast), Hep-G2 (Hepatoma), and SK-OV-3 (ovarian) which exhibited the superior cytotoxicity of complex [C<sub>31</sub>H<sub>35</sub>O<sub>4</sub>SeRuCl] as compared to other analogs on selective cancer phenotypes.Communicated by Ramaswamy H. Sarma.
|
30124119 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The compounds were synthesized via microwave-assisted methods and screened for their cytotoxic activity against liver HepG-2, lung NCI-H522, melanoma A-375, pancreatic MIA PaCa-2 and colon CaCo-2 human cancer cell lines using MTT assay.
|
27539315 |
2017 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Overexpression of miR-374 sensitized PANC-1 and MIA PaCa-2 cells toward carbon ion beam radiation. miRNA miR-374 has the potential to be a new radiosensitizer for carbon ion beam radiotherapy and a new biomarker to determine the optimal treatment for cancer.
|
27665739 |
2016 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, the nanocomposite functions as a targetable drug nanocarrier and a NIR-laser inducible hyperthermic material that is capable of ablating PANC-1 and MIA PaCa-2 cancer cell lines.
|
28059418 |
2017 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A genetically altered luciferase MIA PaCa-2 xenograft model was used to image in real time and determine effects on systemic malignant human cancer.
|
22258068 |
2012 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The anticancer effects of HCA on MIA PaCa‑2 cells were exhibited at a lower concentration than gemcitabine, a potent cancer drug.
|
26397991 |
2015 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The protein from human melanoma cell lines and tumors is called melanoma inhibitory activity (MIA) (Blesch et al.[1994] Cancer Res.
|
9097023 |
1997 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Three representative pancreatic cancer cell lines, AsPC-1, MIA PaCa-2 and PANC-1, with a normal pancreatic ductal epithelial cell line HPDE as a control, were examined with this method, and 19 genes were upregulated twofold or more in all the three cancer cell lines after MeTA; 16 of these 19 genes have not been detected previously when using a conventional DNA demethylating agent, 5-aza-2'-deoxycytidine.
|
21723258 |
2011 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The Food and Drug Administration (FDA) has approved a few TMs for OC: CA125 (cancer antigen 125; monitoring), HE4 (Human epididymis protein; monitoring), ROMA (Risk Of Malignancy Algorithm; HE4+CA125; prediction of malignancy) and OVA1 (Vermillion's first-generation Multivariate Index Assay [MIA]; prediction of malignancy).
|
30529050 |
2019 |
|
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Differentially Expressed microRNAs in MIA PaCa-2 and PANC-1 Pancreas Ductal Adenocarcinoma Cell Lines are Involved in Cancer Stem Cell Regulation.
|
31510100 |
2019 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
This investigation suggested that dietary consumption of omega-3 PUFAs (250-1000 μM) has a significant effect on the proliferation and WIF1 gene expression of the MIA PaCa-2 cancer cell line but no effect on the promoter methylation of this gene.
|
30649640 |
2019 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Upregulation of HMG1 leads to melanoma inhibitory activity expression in malignant melanoma cells and contributes to their malignancy phenotype.
|
12665595 |
2003 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The melanoma inhibitory activity (MIA) protein is a clinically valuable marker in patients with malignant melanoma as enhanced values diagnose metastatic melanoma stages III and IV.
|
12592021 |
2003 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
MIA has a pivotal role in the progression and metastasis of melanoma; MIA2 and TANGO have been suggested to possess tumor-suppressive functions; and OTOR is uniquely expressed in cochlea of the inner ear.
|
29655307 |
2018 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Uncovering new potential downstream effectors working via activation of YBX1 supports the important role of MIA in melanoma.
|
23672612 |
2013 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The protein from human melanoma cell lines and tumors is called melanoma inhibitory activity (MIA) (Blesch et al.[1994] Cancer Res.
|
9097023 |
1997 |
|
melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, PEDF downregulated S100β and melanoma inhibitory activity, which are widely used in the pathological diagnosis of melanoma.
|
21673604 |
2011 |
|
melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Seven human tumour xenografts were analysed in nude mice; five tumours (KEsC-2, oesophageal carcinoma; FA-6, pancreatic carcinoma; SEKI, melanoma; Lu-65A and Lu-61, lung carcinomas) were associated with hypercalcaemia and two tumours (MIA PaCa-2, pancreatic carcinoma; PLC/PRF/5, hepatocellular carcinoma) with normocalcaemia.
|
1997102 |
1991 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
All melanomas tested (n = 19) expressed high levels of MIA mRNA and protein.
|
12014625 |
2002 |
|
melanoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Down-regulation of COOH-terminal binding protein expression in malignant melanomas leads to induction of MIA expression.
|
12384563 |
2002 |